NCT02639546: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAS, RAF, MEK, ERK
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 6 Months to 30 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Must have tumor with known or expected RAS/RAF/MEK/ERK pathway involvement; For dose escalation phase, must be under 18 yrs old; For dose expansion phase, must be under 30 years old

Comments are closed.

Up ↑